Peptron, Inc. (KOSDAQ:087010)

Market Cap	5.37T +34.9%
Revenue (ttm)	5.98B +39.3%
Net Income	-16.62B
EPS	-715.16
Shares Out	23.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	191,253
Open	237,000
Previous Close	230,500
Day's Range	227,500 - 254,500
52-Week Range	159,000 - 392,500
Beta	0.56
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Peptron

Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. It develops PAb 001 for cancer therapy; SR-Exenatide (PT320) for Parkinson’s and other neurodegenerative disease; SR-Octreotide for the treatment of acromegaly; and Dernak filler for bioequivalence. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 087010

Financial Performance

In 2025, Peptron's revenue was 5.63 billion, an increase of 78.76% compared to the previous year's 3.15 billion. Losses were -13.82 billion, -37.26% less than in 2024.